Softhale’s Board of Directors is pleased to welcome Dr. Jan-Torsten Tews as Chief Executive Officer

Dr. Jan-Torsten Tews CEO - René Verkaart

October 5th, 2017 Diepenbeek, Belgium

Dr. Jan-Torsten Tews will join Softhale NV on October 1st, 2017 as CEO.

Dr. Jan-Torsten Tews joins from Sandoz, where he led the Global Respiratory Business of Novartis’s Gx Division over the last 8 years. Prior to joining Sandoz, he was Head of Respiratory Europe at Teva Pharmaceuticals and had previously worked for GlaxoSmithKline, Germany, in a broad range of leadership positions across Marketing, Sales and Health Outcomes. Being professionally focused on the treatment of asthma and COPD over 20 years and from different perspectives, Dr. Jan-Torsten Tews brings a vast experience in development, marketing and sales of inhalation products.

A German national, Jan-Torsten Tews earned his M.D. from University of Hamburg, Germany, and holds an MBA from Northwestern University’s Kellogg School of Management (Evanston, US) as well as a diploma in Health Economics from the Stockholm School of Economics (Sweden).

Commenting on his new role, Jan-Torsten said:

“I feel privileged and honoured to join Softhale and its proprietary unique inhalation technology at this exciting time. Facing a still growing number of asthma and COPD patients and knowing, that especially the device technology still represents an area of unmet medical needs, I see a fantastic opportunity to help treat millions of patients in the near future.”

The Board of Directors is excited that Softhale has secured such an experienced and talented executive. Respiratory disease remains a growing unmet medical need and Jan-Torsten will help the company address this need.
Furthermore, they would like to take the opportunity to express their gratitude to Mr. Frank Pieters, who has led Softhale NV as Executive Chairman over the past 10 months, Mr. Pieters will continue as Non-Executive Chairman of Softhale’s Board.”

About Softhale NV

Softhale is a Belgium based medical device company focused on the development of Soft Mist Inhalation (SMI) devices for the delivery of pharmaceutical drugs to the lungs. Softhale is currently designing and creating a propellant-free, purely mechanical device to be used for worldwide generic and non-generic pharmaceutical development and approval processes, offering innovative as well as cost-optimized device components. These developments address a growing potential global market of respiratory diseases.


Dr. med. Jan-Torsten Tews, +32 474 621675 – email or or LinkedIn.